SEC Form 4 · accession 0001140361-16-055904
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen LaHue Cartt
Officer — President and CEO · Director
Period of report
Feb 28, 2016
Accepted (ET)
Mar 1, 2016 · 9:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2016 | A | 200,000 | — | A | 200,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $3.64 | Feb 28, 2016 | A | 1,000,000 | A | Feb 28, 2016 | Feb 28, 2026 | Common Stock | 1,000,000 | 1,000,000 | D |
Explanation of responses
- F1Such shares of restricted common stock were granted by the Board and vest in two equal installments on August 31, 2016 and February 28, 2017, conditioned on the reporting person's continued employment, as detailed in his employment agreement.
- F2The stock options vest in 48 equal monthly installments commencing on March 31, 2016, conditioned on the reporting person's continued employment, as detailed in his employment agreement.